A BILL 
To amend the 21st Century Cures Act to provide for designa-
tion of institutions of higher education that provide re-
search, data, and leadership on continuous manufac-
turing as National Centers of Excellence in Continuous 
Pharmaceutical Manufacturing, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘National Centers of 
4
Excellence in Continuous Pharmaceutical Manufacturing 
5
Act of 2019’’. 
6
03:53 Nov 01, 2019
H4866
2 
•HR 4866 IH
SEC. 2. NATIONAL CENTERS OF EXCELLENCE IN CONTIN-
1
UOUS PHARMACEUTICAL MANUFACTURING. 
2
(a) IN GENERAL.—Section 3016 of the 21st Century 
3
Cures Act (21 U.S.C. 399h) is amended to read as follows: 
4
‘‘SEC. 3016. NATIONAL CENTERS OF EXCELLENCE IN CON-
5
TINUOUS 
PHARMACEUTICAL 
MANUFAC-
6
TURING. 
7
‘‘(a) IN GENERAL.—The Secretary of Health and 
8
Human Services, acting through the Commissioner of 
9
Food and Drugs— 
10
‘‘(1) shall solicit and, beginning not later than 
11
180 days after the date of enactment of the National 
12
Centers of Excellence in Continuous Pharmaceutical 
13
Manufacturing Act of 2019, receive requests from 
14
institutions of higher education to be designated as 
15
a National Center of Excellence in Continuous Phar-
16
maceutical Manufacturing (in this section referred to 
17
as a ‘National Center of Excellence’) to support the 
18
advancement and development of continuous manu-
19
facturing; and 
20
‘‘(2) shall so designate any institution of higher 
21
education that— 
22
‘‘(A) requests such designation; and 
23
‘‘(B) meets the criteria specified in sub-
24
section (c). 
25
03:53 Nov 01, 2019
H4866
3 
•HR 4866 IH
‘‘(b) REQUEST FOR DESIGNATION.—A request for 
1
designation under subsection (a) shall be made to the Sec-
2
retary at such time, in such manner, and containing such 
3
information as the Secretary may require. Any such re-
4
quest shall include a description of how the institution of 
5
higher education meets or plans to meet each of the cri-
6
teria specified in subsection (c). 
7
‘‘(c) CRITERIA FOR DESIGNATION DESCRIBED.—The 
8
criteria specified in this subsection with respect to an in-
9
stitution of higher education are that the institution has, 
10
as of the date of the submission of a request under sub-
11
section (a) by such institution— 
12
‘‘(1) physical and technical capacity for re-
13
search and development of continuous manufac-
14
turing; 
15
‘‘(2) scalable manufacturing knowledge-sharing 
16
networks with other institutions of higher education, 
17
large and small biopharmaceutical manufacturers, 
18
generic and nonprescription manufacturers, contract 
19
manufacturers, and other entities; 
20
‘‘(3) proven capacity to design and demonstrate 
21
new, highly effective technology for use in contin-
22
uous manufacturing; 
23
03:53 Nov 01, 2019
H4866
4 
•HR 4866 IH
‘‘(4) a track record for creating and transfer-
1
ring knowledge with respect to continuous manufac-
2
turing; 
3
‘‘(5) the potential to train a future workforce 
4
for research on and implementation of continuous 
5
manufacturing; and 
6
‘‘(6) the potential to participate in and lead a 
7
continuous manufacturing technology partnership 
8
with other institutions of higher education, large and 
9
small biopharmaceutical manufacturers, generic and 
10
nonprescription manufacturers, contract manufac-
11
turers, and other entities— 
12
‘‘(A) to support companies with continuous 
13
manufacturing in the United States; 
14
‘‘(B) to support Federal agencies with 
15
technical assistance for continuous manufac-
16
turing; 
17
‘‘(C) with respect to continuous manufac-
18
turing, to organize and conduct research and 
19
development activities needed to create new and 
20
more effective technology, capture and dissemi-
21
nate expertise, create intellectual property, and 
22
maintain technological leadership; 
23
03:53 Nov 01, 2019
H4866
5 
•HR 4866 IH
‘‘(D) to standardize systems and ap-
1
proaches for designing continuous manufac-
2
turing; and 
3
‘‘(E) to develop a plan to establish a con-
4
tinuous manufacturing workforce. 
5
‘‘(d) TERMINATION
OF DESIGNATION.—The Sec-
6
retary may terminate the designation of any National Cen-
7
ter of Excellence designated under this section if the Sec-
8
retary determines such National Center of Excellence no 
9
longer meets the criteria specified in subsection (c). Not 
10
later than 60 days before the effective date of such a ter-
11
mination, the Secretary shall provide written notice to the 
12
National Center of Excellence, including the rationale for 
13
such termination. 
14
‘‘(e) CONDITIONS FOR DESIGNATION.—As a condi-
15
tion of designation as a National Center of Excellence 
16
under this section, the Secretary shall require that an in-
17
stitution of higher education enter into an agreement with 
18
the Secretary under which the institution agrees— 
19
‘‘(1) to collaborate directly with the Food and 
20
Drug Administration to publish the reports required 
21
by subsection (g); 
22
‘‘(2) to share data with the Food and Drug Ad-
23
ministration regarding best practices and research 
24
generated through the funding under subsection (f); 
25
03:53 Nov 01, 2019
H4866
6 
•HR 4866 IH
‘‘(3) to provide an annual report to the Food 
1
and Drug Administration regarding the institution’s 
2
activities under this section; and 
3
‘‘(4) to develop, along with industry partners 
4
and another institution or institutions designated 
5
under this section, if any, a roadmap for developing 
6
a continuous manufacturing workforce. 
7
‘‘(f) FUNDING.— 
8
‘‘(1) IN GENERAL.—The Secretary shall award 
9
funding to the National Centers of Excellence des-
10
ignated under this section for the purpose of study-
11
ing and recommending improvements to continuous 
12
manufacturing, including such improvements as may 
13
enable the Centers— 
14
‘‘(A) to continue to meet the conditions 
15
specified in subsection (e); 
16
‘‘(B) to submit reports under subsection 
17
(e)(3); and 
18
‘‘(C) to expand capacity for research on, 
19
and development of, continuing manufacturing. 
20
‘‘(2) AUTHORIZATION
OF
APPROPRIATIONS.— 
21
There is authorized to be appropriated to carry out 
22
this subsection $80,000,000 for the period of fiscal 
23
years 2021 through 2025. 
24
03:53 Nov 01, 2019
H4866
7 
•HR 4866 IH
‘‘(3) RULE
OF
CONSTRUCTION.—Nothing in 
1
this section shall be construed as precluding a Na-
2
tional Center for Excellence designated under this 
3
section from receiving funds under any other provi-
4
sion of this Act or any other Federal law. 
5
‘‘(g) ANNUAL REVIEW AND REPORTS.— 
6
‘‘(1) ANNUAL
REPORT.—Beginning not later 
7
than one year after the date on which the first des-
8
ignation is made under subsection (a), and annually 
9
thereafter, the Secretary shall— 
10
‘‘(A) submit to Congress a report describ-
11
ing the activities, partnerships and collabora-
12
tions, Federal policy recommendations, previous 
13
and continuing funding, and findings of, and 
14
any other applicable information from, the Na-
15
tional Centers of Excellence designated under 
16
this section; and 
17
‘‘(B) make such report available to the 
18
public in an easily accessible electronic format 
19
on the website of the Food and Drug Adminis-
20
tration. 
21
‘‘(2) REVIEW OF NATIONAL CENTERS OF EX-
22
CELLENCE AND POTENTIAL DESIGNEES.—The Sec-
23
retary shall periodically review the National Centers 
24
of Excellence designated under this section to ensure 
25
03:53 Nov 01, 2019
H4866
8 
•HR 4866 IH
that such National Centers of Excellence continue to 
1
meet the criteria for designation under this section. 
2
‘‘(3) REPORT ON LONG-TERM VISION OF FDA 
3
ROLE.—Not later than 2 years after the date on 
4
which the first designation is made under subsection 
5
(a), the Secretary, in collaboration with the National 
6
Centers of Excellence designated under this section, 
7
shall submit a report to the Congress on the long- 
8
term vision of the Department of Health and 
9
Human Services on the role of the Food and Drug 
10
Administration in supporting continuous manufac-
11
turing, including— 
12
‘‘(A) a national framework of principles re-
13
lated to the implementation and regulation of 
14
continuous manufacturing; and 
15
‘‘(B) a plan for the development of Federal 
16
regulations and guidance for how continuous 
17
manufacturing can be incorporated into the de-
18
velopment, review, and approval process for 
19
drugs and biological products. 
20
‘‘(h) DEFINITIONS.—In this section: 
21
‘‘(1) BIOLOGICAL
PRODUCT.—The term ‘bio-
22
logical product’ has the meaning given such term in 
23
section 351(i) of the Public Health Service Act (42 
24
U.S.C. 262(i)). 
25
03:53 Nov 01, 2019
H4866
9 
•HR 4866 IH
‘‘(2) 
CONTINUOUS
MANUFACTURING.—The 
1
term ‘continuous manufacturing’— 
2
‘‘(A) means a process where the input ma-
3
terials are continuously fed into and trans-
4
formed within the process, and the processed 
5
output materials are continuously removed from 
6
the system; and 
7
‘‘(B) consists of an integrated process that 
8
consists of a series of two or more unit oper-
9
ations. 
10
‘‘(3) DRUG.—The term ‘drug’ has the meaning 
11
given such term in section 201 of the Federal Food, 
12
Drug, and Cosmetic Act (21 U.S.C. 321). 
13
‘‘(4) INSTITUTION OF HIGHER EDUCATION.— 
14
The term ‘institution of higher education’ has the 
15
meaning given such term in section 101(a) of the 
16
Higher Education Act of 1965 (20 U.S.C. 1001(a)). 
17
‘‘(5) SECRETARY.—The term ‘Secretary’ means 
18
the Secretary of Health and Human Services, acting 
19
through the Commissioner of Food and Drugs.’’. 
20
(b) TRANSITION RULE.—Section 3016 of the 21st 
21
Century Cures Act (21 U.S.C. 399h), as in effect on the 
22
day before the date of the enactment of this section, shall 
23
03:53 Nov 01, 2019
H4866
10 
•HR 4866 IH
apply with respect to grants awarded under such section 
1
before such date of enactment. 
2
Æ 
03:53 Nov 01, 2019
H4866
